MetaDeq Diagnostics

Redefining Liver Health Through Early Detection and Monitoring: A Paradigm Shift

HeparDx: A blood test for MASH and Liver Fibrosis focused on detecting lobular inflammation and hepatocyte ballooning

In June 2023, the American Diabetes Association Recommended that all Type 2 Diabetes patients are screened for MASLD (NAFLD).

In June 2023, the multinational liver societies AASLD, EASL and ALEH announced a change in nomenclature for the diseases formerly described as NAFLD and NASH. Nonalcoholic fatty liver disease (NAFLD) is now metabolic dysfunction-associated steatotic liver disease (MASLD); metabolic dysfunction-associated steatohepatitis (MASH) is the replacement term for nonalcoholic steatohepatitis (NASH).

The Need for Simple and Accurate Non-invasive Testing for MASH and Liver Fibrosis

>25% of US adults have MASLD (~62m), with ~20% progressing to MASH (~13m)

Source: Int J Mol Sci, 2019

MASH has been estimated to grow to a $26bn market by 2035 (ROTH•MKM)

HeparDx is a novel liquid biopsy solution to accurately diagnose, stage and monitor MASH

Peer-reviewed and published clinical data in 250 patients

We Address the Challenges of Diagnosing MASH and Liver Fibrosis

Currently, MASH needs to be diagnosed with an ultrasound-guided liver biopsy – which has significant drawbacks

 
 
 
The Diagnosis Problem
Currently, MASH needs to be diagnosed with an ultrasound-guided liver biopsy, which extracts a piece of the liver.
 
This procedure can cause organ damage, pain, and in most cases, bleeding, and intrinsically has high rates of sample error.
 
 
The procedure is high cost (~$6,000 per diagnosis in the US) and is usually performed in an out-patient setting.
 
Liver biopsy for drug testing has an 80% screen failure rate, wasting money and harming patients. Many MASLD, MASH, and liver fibrosis drugs need better diagnostics.
Accurate, scalable and reproducible non-invasive tests are needed to replace liver biopsies for diagnosis & monitoring and drug discovery.
Currently, NASH needs to be diagnosed with an ultrasound-guided liver biopsy, which extracts a piece of the liver.
This procedure can cause organ damage, pain, and in most cases, bleeding, and intrinsically has high rates of sample error.
The procedure is high cost (~$6,000 per diagnosis in the US) and is usually performed in an out-patient setting.
Liver biopsy for drug testing has an 80% screen failure rate, wasting money and harming patients. Many NAFLD, NASH, and liver fibrosis drugs need better diagnostics.
Accurate, scalable and reproducible non-invasive tests are needed to replace liver biopsies for diagnosis & monitoring and drug discovery.

Our Solution

Metadeq Diagnostics has developed HeparDx – a blood test that, based on a multi-center prospective study, can accurately diagnose and stage MASH and liver fibrosis

Why HeparDx?

  • HeparDx can accurately diagnose and stage MASH with high accuracy, with the goal to aid physicians in replacing liver biopsy procedures

  • The test has high accuracy of >95% vs. liver biopsy in diagnosing the presence or absence of MASH. In comparison, other tests are below the 90% threshold

  • Clinical data from a prospective multi-center trial in 250 patients undergoing liver biopsies has been peer-reviewed and published in a leading hepatology journal, and correlates two blood biomarkers with MASH activity and fibrosis in the liver

  • The March 14, 2024 FDA approval of Madrigal Pharmaceuticals’ Rezdiffra™ (resmetirom) for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (F2-F3 stages) will require a faster and more accurate way for patient diagnosis and monitoring, to aid physicians, as well as payors, in monitoring drug response

  • Abstracts presented at EASL 2024 show that HeparDx can accurately detect inflammation and ballooning as individual components.

  • Over the next 3+ years, as additional therapeutics are approved by the FDA, diagnosis of MASH by the primary care physician is crucial

Key Messages

  • Published clinical trial data in high-impact peer-reviewed journal from a 250-patient multi-center prospective study
  • Potential competitive advantage in MASH with accuracy >95% using a single biomarker
  • Identifiable path to FDA approval via a 510(k); breakthrough device designation
  • Potential for point-of-care testing to expand the treating physician base beyond hepatologists

Clinical Data & FDA

  • The approval of Rezdiffra™ (resmetirom) and subsequent near-term MASH therapeutics will need an accurate, non-invasive companion diagnostic
  • Clinical trial results continue to be slowed by high screen failure rates
  • Total MASH addressable market (TAM) >$23 billion

In June 2023, the American Diabetes Association updated their guidelines to emphasize the importance of early detection of MASLD (NAFLD) in people with Type 2 Diabetes

The CDC estimates that 37.3M people in the US have diabetes 
(By the Numbers: Diabetes in America | Diabetes | CDC)

Diabetes and liver disease are closely linked, and it is essential that healthcare professionals have the most current information to effectively detect and manage this disease.

Scroll to Top